查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011526

疫苗契约製造市场：2026-2032年全球市场预测（依疫苗类型、技术平台、服务内容、应用、研发阶段及最终用户划分）

Vaccine Contract Manufacturing Market by Vaccine Type, Technology Platform, Service Offering, Application Type, Application Stage, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，疫苗契约製造市场价值将达到 60.4 亿美元，到 2026 年将成长至 65.6 亿美元，到 2032 年将达到 114.3 亿美元，复合年增长率为 9.53%。

主要市场统计数据
基准年 2025 60.4亿美元
预计年份：2026年 65.6亿美元
预测年份 2032 114.3亿美元
复合年增长率 (%) 9.53%

从策略观点来看，契约製造是塑造公共卫生结果、加快商业化速度和增强跨境韧性的关键能力。

疫苗契约製造环境已从单一的供应解决方案发展成为支持全球公共卫生、市场化药物研发和地缘政治韧性的策略支柱。製造商、研发人员和政策制定者日益将契约製造视为一种灵活可配置的能力，它会影响专案进度安排、监管风险和病患获取途径。因此，决策者需要一个整合的观点，将技术能力与涵盖製剂、填充和包装、分析表征以及物流等各个环节的服务协调联繫起来。

技术创新、监管灵活性和综合服务模式如何重新定义契约製造的竞争优势。

过去五年，企业采购生产和研究服务的方式发生了显着变化。 mRNA和病毒载体平台的进步、模组化和一次性设施架构的普及，以及基于细胞和无细胞技术的兴起，拓宽了可行的专案设计范围。这些技术变革也带来了营运方面的进步。更先进的分析技术缩短了研发週期，灌装和包装流程的自动化降低了变异性，并加快了规模化生产进程。

评估近期美国关税趋势如何重塑疫苗製造领域的筹资策略、供应商合格和区域投资决策。

美国新的贸易政策和关税方案带来了新的成本和营运方面的考量，正在影响全球供应链。关税相关的摩擦增加了进口原料、一次性零件和专用设备的总到岸成本，促使赞助商和製造商重新评估其筹资策略策略。为此，各组织正在实现供应商多元化，认证关键投入品的区域替代品，并加快库存规划，以确保专案持续运作。

基于细分的详细洞察，将疫苗模式、平台架构、服务产品、部署阶段和最终用户行为与伙伴关係和投资选择连结起来。

精准的细分观点能够清楚揭示策略价值的集中之处以及能力缺口所在。在分析DNA疫苗、灭活疫苗、减毒疫苗、mRNA疫苗、类毒素疫苗和病毒载体疫苗等多种疫苗类型时，企业必须将技术要求与生产製造专长相匹配，因为每种疫苗类型都有其独特的上游和下游製程要求以及监管环境。技术平台进一步细分了这些要求。以细胞为基础的方法分为贴壁培养和悬浮培养，而无细胞、卵源性和合成胜肽平台则各自面临着规模化生产和分析方面的挑战。

区域生产能力、监管多样性和供应链走廊决定了疫苗生产投资在哪些方面能够带来策略韧性和商业性优势。

区域趋势决定了在哪些地区投资产能和技术能力能带来最大的策略回报。在美洲，人们倾向于快速获得先进的生物製剂平台，并与伙伴关係建立良好的关係，透过联合部署技术团队和强大的分析能力来缩短研发週期。该地区的监管路径强调与国际标准接轨，并通常支持优先项目的快速核准，这反过来又促进了本地生产以及先进填充和包装能力的开发。

策略行动、产能投资和伙伴关係模式，重点是扶持疫苗生产领域表现优异的契约製造製造商和服务供应商。

疫苗契约製造领域的企业竞争格局受垂直整合、平台专业化和服务范围策略投资的影响。主要企业透过整合分析服务和研发专长来脱颖而出，从而减少技术转移摩擦，缩短临床试验时间。而其他企业则专注于模组化生产能力和灵活的一次性生产，以适应多种治疗方法，而无需进行大规模设备改造。从产能共用协议到技术授权和合资模式，伙伴关係和策略伙伴关係已成为弥合产能缺口和加速向新地区扩张的常用机制。

为加速疫苗计画的成功，提出协调技术能力、供应链韧性、合约模式和社区参与的实用建议。

为了将洞察转化为竞争优势，产业领导者应专注于有针对性、可操作的步骤，以降低专案风险并加速商业化进程。首先，应优先考虑能力匹配，将疫苗研发模式和阶段与合作伙伴的专长领域相匹配。这将缩短技术转移时间，并最大限度地减少规模化生产过程中的返工。其次，应透过认证多家关键原料和一次性组件供应商，并制定包含区域采购和库存缓衝的紧急时应对计画，来增强供应链的稳健性。

透明的混合方法研究设计，结合对关键相关人员的访谈、监管和技术证据以及交叉检验的综合分析，为策略决策提供支援。

本研究采用混合方法，旨在检验来自多个资料来源和相关人员观点的证据，从而支持上述发现。主要数据透过契约製造、疫苗研发公司、监管顾问和采购机构高管进行结构化访谈收集，以了解实际营运和策略重点。二级资讯来源包括同侪审查文献、监管指导文件、专利趋势和企业技术揭露，用于检验有关技术趋势和能力的论点。

整合策略挑战，展现综合能力设计、供应链韧性和伙伴关係协调如何决定专案和公共卫生结果。

技术创新、监管现代化和地缘政治压力等多种因素共同作用，重新定义了契约製造的优先事项。成功的机构将平台特定的卓越技术与一体化的服务交付、稳健的供应链策略以及基于当地实际情况的投资决策相结合。本分析强调了将从mRNA和病毒载体到蛋白质平台等不同疫苗生产方式的要求与相应的生产架构和分析能力相匹配的重要性，同时也要考虑生物技术公司、政府机构和製药公司采购行为的实际情况。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：疫苗契约製造：依疫苗类型划分

  • DNA
  • 失活
  • 活病毒疫苗
  • mRNA
  • 类毒素
  • 病毒载体

第九章：按技术平台分類的疫苗契约製造市场

  • 基于细胞
    • 黏附培养
    • 悬浮培养
  • 无细胞
  • 蛋製品
  • 合成胜肽

第十章：疫苗契约製造市场（依服务类型划分）

  • 分析服务
  • 原料药生产
  • 填充和精加工
  • 药学服务
  • 后勤
  • 包装

第十一章：按应用分類的疫苗契约製造市场

  • 预防性疫苗
  • 治疗性疫苗

第十二章：按应用阶段分類的疫苗契约製造市场

  • 临床阶段
    • 第一阶段
    • 第二阶段
    • 第三阶段
  • 商业阶段

第十三章：疫苗契约製造市场：依最终用户划分

  • 生技公司
  • 政府机构
  • 製药公司

第十四章：疫苗契约製造市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：疫苗契约製造市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：疫苗契约製造市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国疫苗契约製造市场

第十八章：中国疫苗契约製造市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc
  • Ajinomoto Co., Inc.
  • Aton（Shanghai）Biotech Co., Ltd.
  • Avid Bioservices, Inc.
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • CSL Limited
  • Curia Global, Inc.
  • Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
  • Emergent BioSolutions Inc.
  • FUJIFILM Diosynth Biotechnologies USA, Inc. by FUJIFILM Corporation
  • Gedeon Richter PLC
  • GlaxoSmithKline PLC
  • ICON PLC
  • IDT Biologika GmbH
  • KBI Biopharma, Inc. by JSR Corporation
  • Klocke Pharma-Service GmbH
  • Lonza Group Ltd.
  • Merck KGaA
  • Moderna, Inc.
  • Pfizer Inc.
  • Pharmaceutical Product Development by Thermo Fisher Scientific Inc.
  • Recipharm AB
  • Serum Institute of India
  • Vetter Pharma-Fertigung GmbH & Co. KG
Product Code: MRR-430D42AA0DC4

The Vaccine Contract Manufacturing Market was valued at USD 6.04 billion in 2025 and is projected to grow to USD 6.56 billion in 2026, with a CAGR of 9.53%, reaching USD 11.43 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.04 billion
Estimated Year [2026] USD 6.56 billion
Forecast Year [2032] USD 11.43 billion
CAGR (%) 9.53%

A strategic orientation that frames vaccine contract manufacturing as a critical capability shaping public health outcomes, commercialization speed, and cross-border resilience

The vaccine contract manufacturing landscape has evolved from a narrowly focused supply solution into a strategic axis of global public health, commercial drug development, and geopolitical resilience. Manufacturers, developers, and policy leaders are increasingly treating contract manufacturing as a configurable capability that shapes program timelines, regulatory risk, and patient access. As a result, decision-makers need an integrated perspective that connects technological competency with service orchestration across formulation, fill-finish, analytical characterization, and logistics.

This introduction sets the stage for that integrated perspective by highlighting how technological advances, regulatory expectations, and geopolitical pressures together create both risk and opportunity. It outlines the critical vectors that influence partner selection and capability investment: vaccine modality diversity, platform complexity, service scope, clinical and commercial stage requirements, and end-user priorities. By linking operational capabilities to strategic outcomes, the narrative that follows helps executive teams prioritize near-term actions-such as securing dual-source supply chains or accelerating validation of single-use systems-while keeping sight of longer-term imperatives like regional manufacturing capacity and workforce continuity. Transitioning from awareness to structured decision-making requires clarity about the interplay between science, regulation, and logistics; the content that follows offers that clarity in actionable terms.

How technological innovation, regulatory agility, and integrated service models are redefining competitive advantage in contract vaccine manufacturing

The past five years have produced transformative shifts that are changing how organizations source manufacturing and scientific services. Advances in mRNA and viral vector platforms, greater acceptance of modular and single-use facility architectures, and the emergence of cell-based and cell-free technologies have expanded the palette of feasible program designs. These technical shifts are accompanied by operational advances: more sophisticated analytics shorten development cycles, and automation in fill-finish reduces variability and accelerates scale-up timelines.

Concurrently, regulatory authorities have signaled a willingness to adopt more adaptive review pathways and rely on real-world data to support post-authorization monitoring. This regulatory evolution encourages sponsors and manufacturers to co-develop validation strategies that are field-ready and data-driven. Market participants are responding by forming deeper, capability-driven partnerships rather than one-off transactional contracts. As a result, contract manufacturers are moving upstream into drug substance work, formulation development, and integrated analytics to become full lifecycle partners. Taken together, these shifts create a new playing field where technological agility, regulatory savvy, and service integration determine competitive advantage and program resilience.

Assessment of how recent United States tariff dynamics are reshaping procurement strategies, supplier qualification, and regional investment decisions across vaccine manufacturing

Emerging trade policies and tariff scenarios in the United States introduced new cost and operational considerations that reverberate across global supply chains. Tariff-related frictions increase the total landed cost of imported raw materials, single-use components, and specialized instrumentation, prompting sponsors and manufacturers to reassess sourcing strategies. In response, organizations are diversifying supplier bases, qualifying regional substitutes for critical inputs, and accelerating inventory planning to protect program continuity.

The tariffs also influence location decisions for capital investments. Investors and strategic teams now weigh the resilience benefits of near-shore or on-shore capacity against the fixed cost advantages of established offshore capabilities. This calculus has prompted greater interest in establishing regional hubs that reduce exposure to cross-border trade policy volatility while preserving access to skilled labor pools and regulatory familiarity. In parallel, contract manufacturers are enhancing supply chain transparency and investing in procurement capabilities to mitigate tariff impacts. These operational responses reduce the likelihood of sudden program interruptions and enable sponsors to maintain timelines by adopting multi-modal logistics and local sourcing strategies where feasible.

Deep segmentation-driven insights that map vaccine modalities, platform architectures, service offerings, application stages, and end-user behaviors to partnership and investment choices

A nuanced segmentation lens clarifies where strategic value is concentrated and where capability gaps persist. When analyzing vaccine type diversity-spanning DNA, inactivated, live attenuated, mRNA, toxoid, and viral vector modalities-organizations must align technical requirements with manufacturing specialization, because each modality carries distinct upstream and downstream process needs and regulatory touchpoints. Technology platforms further stratify requirements: cell-based approaches are divided between adherent cell culture and suspension cell culture, while cell-free, egg-based, and synthetic peptide platforms introduce their own scale-up and analytical challenges.

Service offering segmentation reveals varying levels of integration and margin potential, with analytical services, drug substance manufacturing, fill-finish, formulation services, logistics, and packaging each demanding specific capabilities and quality systems. Application type differentiation into preventive and therapeutic vaccines influences batch release strategies, potency assays, and post-market surveillance approaches. Application stage is also material to partner selection: clinical-stage programs-spanning Phase I, Phase II, and Phase III studies-require flexible manufacturing and rapid change control, whereas commercial-stage programs demand validated capacity, sustained supply agreements, and mature quality management systems. Finally, end-user categories-biotech companies, government agencies, and pharmaceutical companies-bring differing procurement behaviors, risk tolerances, and contracting preferences, which in turn shape the structure of commercial contracts and technical transfer expectations.

Regional capacity, regulatory diversity, and supply chain corridors that determine where vaccine manufacturing investments yield strategic resilience and commercial advantage

Regional dynamics determine where investments in capacity and capability will deliver the greatest strategic returns. The Americas prioritize rapid access to advanced biologics platforms and tend to favor partnerships that compress development timelines through co-located technical teams and robust analytics. Regulatory pathways in the region emphasize alignment with international standards and often support accelerated access for priority programs, which in turn incentivizes local manufacturing and advanced fill-finish capabilities.

Europe, Middle East & Africa present a diverse regulatory and commercial tapestry that rewards flexible, regionally distributed manufacturing footprints. In these regions, harmonization efforts and cross-border procurement programs make strategic collaboration attractive, particularly when governments and agencies seek to build resilience. Asia-Pacific is characterized by a mix of high-capacity industrial infrastructure and emerging localized innovation hubs; market participants there emphasize scalable platforms, cost-efficient production, and increasingly sophisticated contract development and manufacturing organizations. Transitioning from regional analysis to action requires an appreciation for how local regulatory expectations, workforce availability, and logistics corridors intersect with technology selection and long-term supply agreements.

Strategic behaviors, capability investments, and partnership models that distinguish high-performing contract manufacturers and service providers in vaccine production

Competitive dynamics among companies operating in the contract vaccine manufacturing space are shaped by strategic investments in vertical integration, platform specialization, and service breadth. Leading organizations are differentiating by embedding analytical services and development expertise to reduce technical transfer friction and shorten time-to-clinic. Others emphasize modular capacity and flexible single-use manufacturing to serve a broader set of modalities without extensive retooling. Alliances and strategic partnerships-ranging from capacity-sharing agreements to technology licensing and joint venture models-are common mechanisms for closing capability gaps and accelerating access to new geographies.

At the capability level, firms that demonstrate consistent quality performance in fill-finish, robust cold chain logistics, and validated formulation approaches secure preferential contracting with large sponsors and public purchasers. Investment in digital quality systems and data integrity frameworks has become a non-negotiable differentiator, enabling remote audits and streamlined regulatory interactions. From a commercial posture, organizations offering tailored contracting terms-such as flexible capacity reservation, milestone-based payments, and shared-risk models-tend to win programs where speed and predictability are equally valued. The competitive landscape thus rewards not only technical excellence but also commercial creativity and operational transparency.

Actionable recommendations for aligning technical capability, supply chain resilience, contracting models, and regional engagement to accelerate vaccine program success

To translate insight into competitive advantage, industry leaders should focus on targeted, actionable steps that reduce program risk and accelerate commercial progress. First, prioritize capability alignment by matching vaccine modality and development stage with partner specialization; this reduces technical transfer time and minimizes rework during scale-up. Next, strengthen supply chain robustness by qualifying multiple suppliers for critical raw materials and single-use components, and by developing contingency plans that include regional sourcing and inventory buffers.

Operationally, invest in modular facility designs and automation in fill-finish to increase throughput without proportionate increases in footprint or headcount. From a commercial perspective, structure contracts that balance flexibility and predictability-combining capacity reservations with performance-based milestones. Leaders should also invest in analytics and digital quality systems to enable remote oversight, faster batch release, and smoother regulatory submissions. Finally, pursue selective partnerships with local stakeholders in priority regions to reduce tariff exposure and accelerate market entry. Implementing these recommendations will require cross-functional coordination between R&D, supply chain, quality, and commercial teams, but doing so yields measurable improvements in program resilience and time-to-market.

Transparent mixed-methods research design combining primary stakeholder interviews, regulatory and technical evidence, and cross-validated synthesis to inform strategic decisions

The research underpinning these insights uses a mixed-methods approach designed to triangulate evidence from multiple data sources and stakeholder perspectives. Primary data were collected through structured interviews with senior leaders across contract manufacturing organizations, vaccine developers, regulatory advisors, and procurement authorities to capture operational realities and strategic priorities. Secondary sources included peer-reviewed literature, regulatory guidance documents, patent landscapes, and company technical disclosures to validate technological trends and capability claims.

Analytical rigor was achieved through cross-validation of qualitative inputs with process-level evidence, such as standard operating procedures, regulatory filing templates, and technology transfer case studies. Data quality safeguards included interview coding, methodological transparency, and the exclusion of claims that could not be corroborated with at least two independent sources. The approach emphasizes reproducibility and traceability so that conclusions about segmentation, regional dynamics, and tariff impacts can be followed from raw inputs through synthesis to executive recommendations. This methodology provides decision-makers with a defensible basis for procurement, capacity planning, and partnership selection.

Synthesis of strategic imperatives demonstrating how integrated capability design, supply chain resilience, and partnership alignment determine program and public health outcomes

The converging forces of technological innovation, regulatory modernization, and geopolitical pressure have redefined the priorities for vaccine contract manufacturing. Organizations that succeed will be those that combine platform-specific technical excellence with integrated service offerings, robust supply chain strategies, and regionally informed investment choices. The analysis highlights the importance of aligning modality requirements-from mRNA and viral vectors to protein-based platforms-with the appropriate manufacturing architectures and analytics capabilities, while also accounting for the realities of procurement behavior across biotech firms, government bodies, and pharmaceutical companies.

In sum, the path to resilient and efficient vaccine manufacturing lies in a balanced strategy that mitigates tariff and supply chain volatility, leverages flexible and automated production capacity, and cultivates transparent commercial partnerships. Executives should view contract manufacturing as a strategic capability to be designed, not merely purchased. By taking a deliberate, integrated approach to partner selection and capability investment, organizations can reduce program risk, compress development timelines, and improve the predictability of product supply to patients and public health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vaccine Contract Manufacturing Market, by Vaccine Type

  • 8.1. DNA
  • 8.2. Inactivated
  • 8.3. Live Attenuated
  • 8.4. MRNA
  • 8.5. Toxoid
  • 8.6. Viral Vector

9. Vaccine Contract Manufacturing Market, by Technology Platform

  • 9.1. Cell Based
    • 9.1.1. Adherent Cell Culture
    • 9.1.2. Suspension Cell Culture
  • 9.2. Cell Free
  • 9.3. Egg Based
  • 9.4. Synthetic Peptide

10. Vaccine Contract Manufacturing Market, by Service Offering

  • 10.1. Analytical Services
  • 10.2. Drug Substance Manufacturing
  • 10.3. Fill Finish
  • 10.4. Formulation Services
  • 10.5. Logistics
  • 10.6. Packaging

11. Vaccine Contract Manufacturing Market, by Application Type

  • 11.1. Preventive Vaccines
  • 11.2. Therapeutic Vaccines

12. Vaccine Contract Manufacturing Market, by Application Stage

  • 12.1. Clinical Stage
    • 12.1.1. Phase I
    • 12.1.2. Phase Ii
    • 12.1.3. Phase Iii
  • 12.2. Commercial Stage

13. Vaccine Contract Manufacturing Market, by End User

  • 13.1. Biotech Companies
  • 13.2. Government Agencies
  • 13.3. Pharmaceutical Companies

14. Vaccine Contract Manufacturing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Vaccine Contract Manufacturing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Vaccine Contract Manufacturing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Vaccine Contract Manufacturing Market

18. China Vaccine Contract Manufacturing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc
  • 19.6. Ajinomoto Co., Inc.
  • 19.7. Aton (Shanghai) Biotech Co., Ltd.
  • 19.8. Avid Bioservices, Inc.
  • 19.9. Catalent, Inc.
  • 19.10. Charles River Laboratories International, Inc.
  • 19.11. CSL Limited
  • 19.12. Curia Global, Inc.
  • 19.13. Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
  • 19.14. Emergent BioSolutions Inc.
  • 19.15. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
  • 19.16. Gedeon Richter PLC
  • 19.17. GlaxoSmithKline PLC
  • 19.18. ICON PLC
  • 19.19. IDT Biologika GmbH
  • 19.20. KBI Biopharma, Inc. by JSR Corporation
  • 19.21. Klocke Pharma-Service GmbH
  • 19.22. Lonza Group Ltd.
  • 19.23. Merck KGaA
  • 19.24. Moderna, Inc.
  • 19.25. Pfizer Inc.
  • 19.26. Pharmaceutical Product Development by Thermo Fisher Scientific Inc.
  • 19.27. Recipharm AB
  • 19.28. Serum Institute of India
  • 19.29. Vetter Pharma-Fertigung GmbH & Co. KG

LIST OF FIGURES

  • FIGURE 1. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ADHERENT CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ADHERENT CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ADHERENT CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSION CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSION CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSION CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL FREE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL FREE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL FREE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY EGG BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY EGG BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY EGG BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SYNTHETIC PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SYNTHETIC PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SYNTHETIC PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LOGISTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LOGISTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LOGISTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PREVENTIVE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PREVENTIVE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GOVERNMENT AGENCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GOVERNMENT AGENCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 180. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 181. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 182. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 184. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 207. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 208. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 209. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 211. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 216. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 217. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 218. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 220. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)